Form 4 for CYTK CYTOKINETICS INC
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001061983-26-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-17 | 2026-03-15 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +27.3K | 165.9K | +20% | $0 |
| DM | 2026-03-17 | 2026-03-15 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +41.2K | 39.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-15 | A | A | 27,306 | $0.00 | 165,935 | D | — | — | |
| 2 | Derivative | Incentive Stock Option (Right to Buy) | 2026-03-15 | A | A | 1,665 | $0.00 | 1,665 | D | $60.06 · 2026-04-15 to 2036-03-14 | 1,665 Common Stock | |
| 3 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2026-03-15 | A | A | 39,527 | $0.00 | 39,527 | D | $60.06 · 2026-04-15 to 2036-03-14 | 39,527 Common Stock |